Veru to Report Fiscal 2026 Second Quarter Financial Results on May 13th
Veru Inc., a biopharmaceutical company focused on cardiometabolic and inflammatory diseases, will report its fiscal 2026 Q2 financial results on May 13, 2026. The company is conducting a Phase 2b PLATEAU trial evaluating its obesity drug enobosarm in combination with semaglutide, aiming to achieve better quality weight loss by preserving lean mass.…